Article Type
Changed
Fri, 01/04/2019 - 11:10
Display Headline
David Henry's JCSO podcast, December 2014

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses articles on the recent approval of ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression and the “small victories” in honing new therapies for hard-to-treat cancers such as ovarian, melanoma, and pancreatic. Quality of care and patient quality of life are the basis for the 3 Original Reports that Dr Henry addresses: one study looks at the impact of patient navigation on diagnostic resolution in women with abnormal screenings for breast or cervical cancer; a second examines how the information and communication needs of Chinese American women with breast cancer can be channeled into improving quality of life after treatment for cancer; and a third reports on how dignity therapy as an intervention in patients with advanced colorectal cancer can positively affect the quality of end-of-life care, treatment choices, and cost efficiency.

References

Author and Disclosure Information

Audio / Podcast
Publications
Legacy Keywords
ramucirumab, gastric cancer, GEJ adenocarcinoma, gastroesophageal junction adenocarcinoma, Chinese American, breast cancer, survivorship care, patient information needs, patient-provider communication, dignity therapy, colorectal cancer, quality of life, quality of care, end-of-life care, diagnostic resolution, patient navigation, ovarian cancer, melanoma, pancreatic cancer, hard-to-treat cancers, PARP inhibitors, ipilimumab, pembrolizumab, FOLFIRINOX, nab-paclitaxel, erlotinib
Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Author and Disclosure Information

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses articles on the recent approval of ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression and the “small victories” in honing new therapies for hard-to-treat cancers such as ovarian, melanoma, and pancreatic. Quality of care and patient quality of life are the basis for the 3 Original Reports that Dr Henry addresses: one study looks at the impact of patient navigation on diagnostic resolution in women with abnormal screenings for breast or cervical cancer; a second examines how the information and communication needs of Chinese American women with breast cancer can be channeled into improving quality of life after treatment for cancer; and a third reports on how dignity therapy as an intervention in patients with advanced colorectal cancer can positively affect the quality of end-of-life care, treatment choices, and cost efficiency.

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses articles on the recent approval of ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression and the “small victories” in honing new therapies for hard-to-treat cancers such as ovarian, melanoma, and pancreatic. Quality of care and patient quality of life are the basis for the 3 Original Reports that Dr Henry addresses: one study looks at the impact of patient navigation on diagnostic resolution in women with abnormal screenings for breast or cervical cancer; a second examines how the information and communication needs of Chinese American women with breast cancer can be channeled into improving quality of life after treatment for cancer; and a third reports on how dignity therapy as an intervention in patients with advanced colorectal cancer can positively affect the quality of end-of-life care, treatment choices, and cost efficiency.

References

References

Publications
Publications
Article Type
Display Headline
David Henry's JCSO podcast, December 2014
Display Headline
David Henry's JCSO podcast, December 2014
Legacy Keywords
ramucirumab, gastric cancer, GEJ adenocarcinoma, gastroesophageal junction adenocarcinoma, Chinese American, breast cancer, survivorship care, patient information needs, patient-provider communication, dignity therapy, colorectal cancer, quality of life, quality of care, end-of-life care, diagnostic resolution, patient navigation, ovarian cancer, melanoma, pancreatic cancer, hard-to-treat cancers, PARP inhibitors, ipilimumab, pembrolizumab, FOLFIRINOX, nab-paclitaxel, erlotinib
Legacy Keywords
ramucirumab, gastric cancer, GEJ adenocarcinoma, gastroesophageal junction adenocarcinoma, Chinese American, breast cancer, survivorship care, patient information needs, patient-provider communication, dignity therapy, colorectal cancer, quality of life, quality of care, end-of-life care, diagnostic resolution, patient navigation, ovarian cancer, melanoma, pancreatic cancer, hard-to-treat cancers, PARP inhibitors, ipilimumab, pembrolizumab, FOLFIRINOX, nab-paclitaxel, erlotinib
Sections
Article Source

PURLs Copyright

Inside the Article